- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06513156
Continuüm van zorg bij ziekenhuispatiënten met opioïdengebruiksstoornissen en infectieuze complicaties als gevolg van drugsgebruik (CHOICE-STAR)
Het continuüm van zorg voor gehospitaliseerde patiënten met opioïdengebruiksstoornissen en infectieuze complicaties van drugsgebruik - NavSTAR, gebruikelijke behandeling, verslavings-/ID-geïntegreerde kliniek om infectiegerelateerde overname te voorkomen
This is a two-group randomized controlled trial conducted at five hospitals across the U.S. designed to test the effectiveness of an Integrated infectious diseases/Substance Use Disorder outpatient clinic (IC) compared to treatment as usual aimed at reducing infection related readmissions and improving health outcomes in people hospitalized with an infection related to injecting opioids or stimulants.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a phase III two arm randomized controlled trial to determine the impact and Integrated infectious diseases (ID) and Substance Use Disorder outpatient clinic (IC) compared to treatment as usual on infection related rehospitalization in individuals hospitalized with infections due to injecting opioids or Stimulants, in the 6 month time period after discharge. This study includes both cost effectiveness and implementation outcomes.
(1) IC will provide facilitated linkage to a clinic providing medical treatment aimed at treating substance use disorder (SUD), resolving the index infection, treating existing ID complications of OUD (HIV, HCV, wounds) and preventing subsequent infections by providing accessible care for infectious diseases and medication for OUD (MOUD) treatment that is integrated into a single appointment and co-located at a single site (either in person or via telemedicine) for a minimum of monthly appointments over a 6 month time period. A feature of the IC will be weekly care coordination meetings between the ID and MOUD providers.
The study will recruit patients during hospitalization for an infection due to injecting opioids or stimulants at four hospital systems (five hospitals) and randomly assign approximately 304 inpatients in 1:1 ratio to IC vs TAU.
Participants will be followed for 12 months.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Rachel Silk
- Telefoonnummer: 301-326-7652
- E-mail: rsilk@ihv.umaryland.edu
Studie Locaties
-
-
District of Columbia
-
Washington D.C., District of Columbia, Verenigde Staten, 20052
- Werving
- George Washington University
-
Onderonderzoeker:
- Irene Kuo, MD
-
Contact:
- Jill Catalanotti, MD
- E-mail: jcatalanotti@mfa.gwu.edu
-
Hoofdonderzoeker:
- Jill Catalanotti, MD
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Werving
- Emory University
-
Hoofdonderzoeker:
- Joseph Carpenter, MD
-
Contact:
- Joseph Carpenter, MD
- E-mail: joseph.edward.carpenter@emory.edu
-
Onderonderzoeker:
- Alina Steck, MD
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21201
- Werving
- University of Maryland Baltimore
-
Onderonderzoeker:
- Edward Traver, MD
-
Hoofdonderzoeker:
- Elana Rosenthal, MD
-
Onderonderzoeker:
- Sarah Kattakuzhy, MD
-
Contact:
- Rachel Silk
- Telefoonnummer: 3013267652
- E-mail: rsilk@ihv.umaryland.edu
-
-
West Virginia
-
Morgantown, West Virginia, Verenigde Staten, 26506
- Werving
- West Virginia University
-
Contact:
- Rebecca Reece, MD
- E-mail: rreece@hsc.wvu.edu
-
Hoofdonderzoeker:
- Rebecca Reece, MD
-
Onderonderzoeker:
- Clinton Cooper, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age ≥ 18 years
- Admitted to study hospital (defined as hospitalized with a primary team that is not Emergency Medicine)
- Injection opioid or stimulant use in past 90 days - per patient self-report
- Active suspected or confirmed qualifying infection (see list) at time of admission.
Qualifying infections:
- Non-vertebral osteomyelitis
- Vertebral osteomyelitis or discitis
- Epidural, subdural, or extradural abscess
- Intracranial or intraspinal abscess
- Native joint septic arthritis
- Prosthetic joint septic arthritis
- Blood stream infection (bacterial or fungal)
- Native valve Endocarditis
- Prosthetic valve endocarditis
- Cardiac Implantable electronic device infection
- Infectious pseudoaneurysm and aneurysm
- Infected vascular graft
- Septic venous thrombosis
- Skin and Soft tissue infection (cellulitis, skin abscess, necrotizing fasciitis)
- Infected skin ulcer
- Orthopedic hardware infection
- Muscle abscess/myositis
- Central nervous system infection (bacterial or fungal)
- Bacterial or fungal ophthalmologic infection
- Other abscess
- Pulmonary septic emboli
- Other acute bacterial or fungal infection deemed appropriate by site study team
Exclusion Criteria:
-
1. Infection due to a cause other than injection drug use, per determination of a site PI.
2. Inability to provide consent due to circumstance (e.g., sedated, intubated), language, or cognitive impairment.
3. Unwilling to provide informed consent 4. Unable to receive potential interventions due to geography 5. On comfort measures or planned for discharge to hospice care 6. Incarcerated at the time of hospitalization 7. Other criteria at the discretion of the site investigator
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Geen tussenkomst: Treatment As Usual
Will receive treatment for infection and opioid or stimulant use disorder per the usual care at each hospital |
|
|
Experimenteel: Integrated Infectious Diseases and Substance Use Disorder Clinic (IC)
The Integrated ID/SUD Clinic will provide facilitated linkage to a clinic providing medical treatment aimed at treating SUD, resolving the sentinel infection, treating existing ID complications of OUD/stimulants (HIV, HCV, wounds) and preventing subsequent infections by providing accessible care for infectious diseases and MOUD treatment that is integrated into a single appointment and co-located at a single site (either in person or via telemedicine) for a minimum of monthly appointments over a 6 month time period. A feature of the IC will be weekly care coordination meetings between the ID and SUD providers. The dual goals of the IC intervention are to 1) to facilitate accessibility to ID and OUD care and 2) to ensure care coordination between outpatient ID and SUD providers. |
Integrated medication for opioid/stimulant use disorder and infectious disease care provided into single appointment either in person or via telemedicine with a minimum of monthly appointments for 6 months. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Infection Rehospitalization
Tijdsspanne: 6 months after discharge for index hospitalization
|
New hospitalization due to infection following discharge for index hospitalization |
6 months after discharge for index hospitalization
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Time to first infection related readmission
Tijdsspanne: 12 months after discharge for index hospitalization
|
Time to first infection related readmission |
12 months after discharge for index hospitalization
|
|
Reason for infection related readmission
Tijdsspanne: 12 months after discharge for index hospitalization
|
Reason for infection related readmission (persistent index infection, new IDU associated infection, other infection) |
12 months after discharge for index hospitalization
|
|
Hospital services utilization
Tijdsspanne: 12 months after discharge for index hospitalization
|
ED visits (Binary, count, time to first ED visit, cause) and Readmission, all cause (binary, count, time to first readmission, cause) |
12 months after discharge for index hospitalization
|
|
Mortality
Tijdsspanne: 12 months after discharge for index hospitalization
|
Death (Binary, time to death, cause of death) |
12 months after discharge for index hospitalization
|
|
Index infection
Tijdsspanne: 3 months after discharge for index hospitalization
|
Completion of antibiotics (binary, reason for incomplete antibiotics); Resolution of index infection (binary) Skilled Nursing Facility (SNF) Admitted to SNF (binary) Discharge type from SNF (planned, PDD, dead, transfer) |
3 months after discharge for index hospitalization
|
|
Other Infections
Tijdsspanne: 12 months after discharge for index hospitalization
|
HCV Active HCV (binary) Clinical evaluation (binary) DAA prescribed (binary) DAA initiated (binary) SVR achieved (binary) HIV Diagnosis status (binary) HIV VL undetectable (binary) ART Taking (binary) Type (pills vs injections) Adherence (# missed doses in last 30 days) PrEP Eligible (CDC Criteria, binary, indication) Offered by healthcare provider (binary) Taking (binary) Type (pills vs injections) Adherence (# missed doses in last 30 days) |
12 months after discharge for index hospitalization
|
|
Skin and soft tissue wounds
Tijdsspanne: 12 months after discharge for index hospitalization
|
Present (binary) Number (count) Per wound Size Location on body Duration (continuous) |
12 months after discharge for index hospitalization
|
|
New infections not requiring hospitalization
Tijdsspanne: 12 months after discharge for index hospitalization
|
|
12 months after discharge for index hospitalization
|
|
Outpatient linkage and retention
Tijdsspanne: 12 months after discharge for index hospitalization
|
|
12 months after discharge for index hospitalization
|
|
Medication for Opioid Use (MOUD)
Tijdsspanne: 12 months after discharge for index hospitalization
|
|
12 months after discharge for index hospitalization
|
|
Medication for stimulant use (MStUD)
Tijdsspanne: 12 months after discharge for index hospitalization
|
|
12 months after discharge for index hospitalization
|
|
Substance Use-Opioid
Tijdsspanne: 12 months after discharge for index hospitalization
|
Ongoing opioid (binary, mode)
|
12 months after discharge for index hospitalization
|
|
Substance Use - Stimulant
Tijdsspanne: 12 months after discharge for index hospitalization
|
Ongoing stimulant use (binary, mode)
|
12 months after discharge for index hospitalization
|
|
Cost Effectiveness
Tijdsspanne: 12 months after discharge for index hospitalization
|
• ICER for quality adjusted life years (QALYs); opioid-free years (OfYs); and infection-free years (IfYs) gained |
12 months after discharge for index hospitalization
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Elana Rosenthal, MD, University of Maryland, Baltimore
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- HP-00111318
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .